-transparent.png){kind=logo}
Human leukocyte antigen (HLA) class I and class II molecules differ with respect to their intracellular pathways and the compartments where they associate with processed antigen. To study possible consequences of these differences for the kinetics of antigen presentation by HLA class I and class II molecules, we analyzed changes in the concentrations of free intracellular calcium ions in influenza virus-specific T cell clones after recognition of specific antigen/HLA complexes. HLA class II-restricted viral antigen presentation by Epstein-Barr virus-transformed B lymphoblastoid cell lines (B-LCL) to CD4+ T cell clones started within 1 h and showed little variability, irrespective of antigen specificity or restriction element tested. In contrast, kinetics of viral antigen presentation by HLA class I molecules to CD8+ T cell clones were slower and differed for three antigen/HLA class I complexes tested. While B-LCL presented antigen by HLA-A2 and by HLA-B37 after at least 2 h, they only started to present antigen in the context of HLA-B7 after more than 4 h. This difference in kinetics did not correlate with differences in bulk transport rates of HLA-A2, HLA-B37, and HLA-B7, but seemed greatly influenced by differential rates of peptide generation. Brefeldin A treatment of B-LCL showed for both HLA class I and class II that de novo synthesized HLA molecules were involved in antigen presentation. Thus, differences between intracellular pathways of HLA class I and class II molecules may result in different kinetics of antigen presentation.
K C Kuijpers, and
F J van Kemenade, and
B Hooibrink, and
J J Neefjes, and
C J Lucas, and
R A van Lier, and
F Miedema
January 2009,
Proceedings of the National Academy of Sciences of the United States of America,
K C Kuijpers, and
F J van Kemenade, and
B Hooibrink, and
J J Neefjes, and
C J Lucas, and
R A van Lier, and
F Miedema
December 2022,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
K C Kuijpers, and
F J van Kemenade, and
B Hooibrink, and
J J Neefjes, and
C J Lucas, and
R A van Lier, and
F Miedema
January 1987,
British medical bulletin,
K C Kuijpers, and
F J van Kemenade, and
B Hooibrink, and
J J Neefjes, and
C J Lucas, and
R A van Lier, and
F Miedema
March 1997,
Journal of immunology (Baltimore, Md. : 1950),
K C Kuijpers, and
F J van Kemenade, and
B Hooibrink, and
J J Neefjes, and
C J Lucas, and
R A van Lier, and
F Miedema
January 1985,
Progress in allergy,
K C Kuijpers, and
F J van Kemenade, and
B Hooibrink, and
J J Neefjes, and
C J Lucas, and
R A van Lier, and
F Miedema
January 1989,
Archivum immunologiae et therapiae experimentalis,
K C Kuijpers, and
F J van Kemenade, and
B Hooibrink, and
J J Neefjes, and
C J Lucas, and
R A van Lier, and
F Miedema
January 2010,
Human immunology,
K C Kuijpers, and
F J van Kemenade, and
B Hooibrink, and
J J Neefjes, and
C J Lucas, and
R A van Lier, and
F Miedema
March 1998,
Tissue antigens,
K C Kuijpers, and
F J van Kemenade, and
B Hooibrink, and
J J Neefjes, and
C J Lucas, and
R A van Lier, and
F Miedema
November 2003,
Journal of virology,
K C Kuijpers, and
F J van Kemenade, and
B Hooibrink, and
J J Neefjes, and
C J Lucas, and
R A van Lier, and
F Miedema
August 1991,
Klinicheskaia meditsina,
